Capsules "Omlos" are used to treat functional disorders of the lower urinary tract with benign prostatic hyperplasia.
Active ingredient: tamsulosin hydrochloride; 1 capsule contains 0.4 mg tamsulosin hydrochloride.
Excipients:
capsule contents: microcrystalline cellulose, methacrylate copolymer dispersion, polysorbate 80, sodium lauryl sulfate, triethyl citrate, talc;
capsule shell: gelatin, indigo FD & C blue 2 (E 132), titanium dioxide (E 171), iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E 172).
Hypersensitivity to tamsulosin hydrochloride, including preparation-induced angioedema, or to any of the excipients; a history of orthostatic hypotension; severe liver failure.
The recommended dose is 1 capsule daily, after breakfast or after the first meal. The capsule should be swallowed whole and not broken or chewed as this will interfere with the modified release of the active ingredient.
Peculiarities
Before starting treatment with tamsulosin, you should undergo a medical examination to identify other comorbidities that can cause the same symptoms as benign prostatic hyperplasia. Before starting treatment, it is necessary to conduct a rectal examination of the prostate gland and, if necessary, a test to determine the level of prostate specific antigen (PSA) at the beginning and at regular intervals during treatment.
pregnant
Not indicated for use by women.
Children
The preparation should not be used in children.
Drivers
No research has been done.
Symptoms.
An overdose of tamsulosin hydrochloride can potentially cause a severe hypotensive effect. Severe hypotensive effects have been observed with varying degrees of overdose.
Treatment.
In the event of a sharp decrease in pressure due to an overdose, supportive therapy should be carried out aimed at restoring the normal function of the cardiovascular system (for example, the patient should take a horizontal position). If this measure does not work, carry out infusion therapy and prescribe vasopressors. It is necessary to monitor renal function and carry out general maintenance therapy. Due to the high degree of binding of tamsulosin to plasma proteins, hemodialysis is hardly advisable.
In order to stop further absorption of the preparation, you can artificially induce vomiting. In case of an overdose of a significant amount of the preparation, the patient needs to wash the stomach with activated charcoal and low-osmotic laxatives, such as sodium sulfate.
Neurological disorders
Often: dizziness (1.3%);
Uncommon: headache;
Rarely: fainting.
From the organs of vision
Not known: blurred vision, blurred vision.
From the side of the heart
Uncommon: palpitations.
Vascular disorders
Uncommon: orthostatic hypotension.
Respiratory-mediastinal disorders
Uncommon: rhinitis.
Not known: epistaxis.
Gastrointestinal Disorders
Uncommon: constipation, diarrhea, nausea, vomiting.
Not known: dry mouth.
This preparation does not require special temperature storage. Keep out of the reach of children.
Shelf life: 3 years.
There are no reviews for this product.